A recent Drug Safety Update article in December 2017 advised that the licences for gadodiamide (Omniscan) and intravenous gadopentetic acid (also known as gadopentetate dimegulumine; Magnevist) will be suspended from 1 February 2018.
Omniscan and intravenous Magnevist are now no longer authorised for use and a product recall of any existing unexpired stock is underway (see Class 2 Medicines Recall).
The linear agents gadobenic acid (also known as gadobenate dimeglumine; MultiHance) and gadoxetic acid (Primovist) should now only be used for liver imaging and when imaging in the delayed phase is required.
Macrocyclic agents gadoteridol (Prohance), gadobutrol (Gadovist), and gadoteric acid (Dotarem) remain authorised, as does gadopentetic acid for intra-articular use only. For further information see the December 2017 Drug Safety Update.
Article citation: Drug Safety Update volume 11 issue 7; February 2018: 3.
Published 6 February 2018